1. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
- Author
-
Elizabeth M. Jaffee, Katherine McDougall, Dung T. Le, Sandy Ferber, Aimee Murphy, Jennifer N. Uram, George A. Fisher, Elizabeth A. Sugar, Robert H. Vonderheide, Daniel A. Laheru, Andrew H. Ko, Todd S. Crocenzi, Dirk G. Brockstedt, and Eric R. Lutz
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Cyclophosphamide ,Immunology ,Phases of clinical research ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antigen ,Pancreatic cancer ,Internal medicine ,medicine ,Immunology and Allergy ,Mesothelin ,Pharmacology ,biology ,business.industry ,Metastatic Pancreatic Adenocarcinoma ,Acquired immune system ,medicine.disease ,GVAX ,Immune checkpoint ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Poster Presentation ,biology.protein ,Molecular Medicine ,Adenocarcinoma ,Nivolumab ,business ,Pancreas ,medicine.drug - Abstract
TPS486 Background: A heterologous prime-boost vaccination strategy using GVAX pancreas and CRS-207 is showing promise in patients with pancreatic adenocarcinoma (PDA) (Le, JCO 2015). Furthermore, blockade of the immune checkpoint programmed death-1 (PD-1) is active in some cancers. Combinatorial strategies aimed at priming tumor antigen-specific T cells while simultaneously blocking negative checkpoints may be necessary to improve outcomes in PDA. GVAX is composed of allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. Nivolumab is an antibody against PD-1. Methods: This is a phase 2 study comparing CY/GVAX and CRS-207 with or without nivolumab in subjects with PDA who failed only one chemotherapy regimen for metastatic disease. Subjects are randomized in a 1:1 ratio to receive either 2 doses of CY/nivolumab/GVAX and 4 doses of nivolumab/CRS-207 (Arm A) or 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm B). The primary objective is to compare OS between Arms A and B. Secondary/exploratory objectives include: assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of Lm- and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response. Clinical trial information: NCT02243371.
- Published
- 2015